Table 4:
SUI Pathway Enrichment Analysis
| # | Pathway | Total Proteins in Pathway | Proteins from Dataset | p-value | FDR p-value |
Affected Proteins from Dataset |
|---|---|---|---|---|---|---|
| 1 | Development_Slit-Robo signaling | 30 | 4 | 3.782E-05 | 0.010 | ROBO4, Actin cytoskeletal, Actin, ACTB |
| 2 | Cytoskeleton remodeling_Keratin filaments | 36 | 4 | 7.896E-05 | 0.010 | Keratin 1, Epiplakin, Actin cytoskeletal, GRB2 |
| 3 | Immune response_Oncostatin M signaling via MAPK | 37 | 4 | 8.810E-05 | 0.010 | MMP-13, TIMP1, GRB2, MMP-1 |
| 4 | Blood coagulation_Blood coagulation | 39 | 4 | 1.087E-04 | 0.010 | Coagulation factor IX, Protein C inhibitor, Coagulation factor X, CPB2 |
| 5 | Immune response_Oncostatin M signaling via JAK-Stat | 22 | 3 | 3.594E-04 | 0.026 | TIMP1, STAT3, MMP-1 |
| 6 | Cell adhesion_ECM remodeling | 55 | 4 | 4.171E-04 | 0.026 | MMP-13, Actin cytoskeletal, TIMP1, MMP-1 |
| 7 | Development_Leptin signaling via JAK/STAT and MAPK cascades | 25 | 3 | 5.295E-04 | 0.029 | TIMP1, GRB2, STAT3 |
| 8 | Signal transduction_mTORC1 downstream signaling | 61 | 4 | 6.201E-04 | 0.029 | p70 S6 kinases, p70 S6 kinase2, Rictor, STAT3 |
| 9 | Role of Tissue factor-induced Thrombin signaling in cancerogenesis | 65 | 4 | 7.892E-04 | 0.033 | MMP-13, MRLC, Actin cytoskeletal, Coagulation factor X |
| 10 | Development_S1P1 receptor signaling via beta-arrestin | 34 | 3 | 1.322E-03 | 0.045 | p70 S6 kinases, p70 S6 kinase2, GRB2 |
The top 10 enriched molecular pathways that mapped to the dataset of biomarkers associated with female SUI. Enriched pathways are identified using MetaCore™. P-value specifies the likelihood that the intersection between the list of affected proteins and a particular network is obtained purely by chance. False discovery rate (FDR)-adjusted p-values are also shown.